PT  - JOURNAL ARTICLE
ED  - Vidt, David G.
AU  - Jones, Edward
AU  - Goldman, Morton
TI  - Lipid formulations of amphotericin B
DP  - 1998 Sep 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 423--427
VI  - 65
IP  - 8
4099  - http://www.ccjm.org/content/65/8/423.short
4100  - http://www.ccjm.org/content/65/8/423.full
SO  - Cleve Clin J Med1998 Sep 01; 65
AB  - Amphotericin B has long been the mainstay in the treatment of systemic fungal infections, but its nephrotoxicity limits the dosage that can be used. New lipid-based forms may allow higher dosing with less nephrotoxicity. Unfortunately, these new forms are substantially more expensive, and data from randomized clinical trials of their relative efficacy are as yet limited.